<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517045</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-017</org_study_id>
    <nct_id>NCT04517045</nct_id>
  </id_info>
  <brief_title>The Study of Dachengqi Decoction Combined With Probiotic L92 to Improve the Prognosis of Patients With Severe Abdominal Hypertension</brief_title>
  <official_title>The Study of Dachengqi Decoction Combined With Probiotic L92 to Improve the Prognosis of Patients With Severe Abdominal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe infections, wounds (burns), and severe pancreatitis often have abdominal&#xD;
      hypertension (IAH), which is an important objective manifestation of acute gastrointestinal&#xD;
      failure in severe patients. Timely diagnosis and effective intervention can improve the&#xD;
      treatment rate of patients. In the early stage, we conducted clinical exploration and&#xD;
      observational research on the treatment of IAH with Dachengqi Decoction and Lactobacillus in&#xD;
      the treatment of critically ill patients including the above diseases, and achieved&#xD;
      significant clinical effects. On this basis, it is planned to verify the protective effect of&#xD;
      Lactobacillus acidophilus L92, Dachengqi Decoction and the combination of the two on the&#xD;
      gastrointestinal mucosal barrier function of patients with IAH and the regulation of the&#xD;
      intestinal flora, and analyze the intestinal mucosal barrier The relationship between&#xD;
      intestinal flora and the prognosis of IAH patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of sepsis within 7 days</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">752</enrollment>
  <condition>Dachengqi Decoction</condition>
  <condition>Probiotic L92</condition>
  <arm_group>
    <arm_group_label>Conventional treatment group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control the primary disease, prevent infection, reduce gastrointestinal decompression, and actively maintain organ function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment plus L92 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment combined with L92</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment plus Dachengqi decoction group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment combined with Dachengqi Decoction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment plus Dachengqi decoction plus L92 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment combined with L92 and Dachengqi Decoction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dachengqi decoction</intervention_name>
    <description>Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial</description>
    <arm_group_label>Conventional treatment plus Dachengqi decoction group</arm_group_label>
    <arm_group_label>Conventional treatment plus Dachengqi decoction plus L92 group</arm_group_label>
    <other_name>probiotic L92</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probiotic L9</intervention_name>
    <description>L92 2 tablets/time, tid, oral or nasal feeding</description>
    <arm_group_label>Conventional treatment plus Dachengqi decoction plus L92 group</arm_group_label>
    <arm_group_label>Conventional treatment plus L92 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Conventional treatment</description>
    <arm_group_label>Conventional treatment group</arm_group_label>
    <arm_group_label>Conventional treatment plus Dachengqi decoction group</arm_group_label>
    <arm_group_label>Conventional treatment plus Dachengqi decoction plus L92 group</arm_group_label>
    <arm_group_label>Conventional treatment plus L92 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion and exclusion criteria and critically ill patients (acute severe&#xD;
             pancreatitis, cervical spinal cord injury) who are 60 years old or older than 18 years&#xD;
             old, expected to be mechanically ventilated in the ICU, and hospitalized for more than&#xD;
             48 hours, replaced intra-abdominal pressure monitoring with bladder pressure&#xD;
             measurement, and repeated on admission The results of the three measurements are â‰¥12&#xD;
             mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have not signed the informed consent; cannot tolerate intra-abdominal&#xD;
             pressure monitoring; pregnant women; patients after bladder surgery; systemic diseases&#xD;
             and recent use of related drugs; previous infections, such as history of tuberculosis&#xD;
             or PPD positive; previous high History of blood pressure, poor blood pressure control&#xD;
             (SBP/DBP&gt;=140mmHg); patients with severe mental illness; long-term use of traditional&#xD;
             Chinese medicine, probiotics, gastric mucosal protectors, proton pump inhibitors,&#xD;
             chemotherapy or immunosuppressive drugs, etc., such as admission The drug was not&#xD;
             discontinued within the previous month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chengjing Gao</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

